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The gene encoding p53 mediates a major tumor suppression pathway that is frequently altered in human
cancers. p53 function is kept at a low level during normal cell growth and is activated in response to various
cellular stresses. The MDM2 oncoprotein plays a key role in negatively regulating p53 activity by either direct
repression of p53 transactivation activity in the nucleus or promotion of p53 degradation in the cytoplasm.
DNA damage and oncogenic insults, the two best-characterized p53-dependent checkpoint pathways, both
activate p53 through inhibition of MDM2. Here we report that the human homologue of MDM2, HDM2, binds
to ribosomal protein L11. L11 binds a central region in HDM2 that is distinct from the ARF binding site. We
show that the functional consequence of L11-HDM2 association, like that with ARF, results in the prevention
of HDM2-mediated p53 ubiquitination and degradation, subsequently restoring p53-mediated transactivation,
accumulating p21 protein levels, and inducing a p53-dependent cell cycle arrest by canceling the inhibitory
function of HDM2. Interference with ribosomal biogenesis by a low concentration of actinomycin D is asso-
ciated with an increased L11-HDM2 interaction and subsequent p53 stabilization. We suggest that L11
functions as a negative regulator of HDM2 and that there might exist in vivo an L11-HDM2-p53 pathway for
monitoring ribosomal integrity.
The p53 tumor suppressor gene mediates a major tumor
suppression pathway in mammalian cells and is frequently al-
tered in human tumors. The p53 protein induces cell cycle
arrest or apoptosis in response to cellular stress by acting as a
sequence-specific transcription factor. Various cellular insults,
including oncogenic stimulation, DNA damage, nucleotide de-
pletion, and hypoxia, trigger distinct signal transduction cas-
cades, leading to p53 stabilization and activation. Inactivation
of this p53-mediated checkpoint function may represent a nec-
essary step for the development of most, if not all, tumors (17,
20, 30).
Accumulating evidence has identified the Mdm2 proto-on-
cogene as a major regulator of p53 (26, 29). Mdm2 was first
cloned as an amplified gene on a murine double-minute chro-
mosome (5) and was subsequently found to be amplified in a
portion of human sarcomas (28) and brain tumors (3, 35). Both
MDM2 and its human homolog, HDM2, can bind to and
inhibit p53 function either by repressing p53’s transcriptional
activity in the nucleus (26, 29, 45) or by targeting p53 for
degradation in the cytoplasm (10, 19; reviewed in reference
47). Deletion of the MDM2 gene in mice results in early em-
bryonic lethality, which can be rescued by the simultaneous
deletion of p53, supporting the notion that p53 is the major
target of MDM2 during development (16, 22).
A number of cellular factors have been identified that di-
rectly bind to or modify MDM2, leading to MDM2 inhibition
and p53 activation in response to various cellular stresses (34).
The two best-characterized p53-mediated checkpoint pathways
are the cellular responses to DNA damage (30) and oncogenic
insults (39). Following DNA damage, several kinases, includ-
ing ATM, Chk1, and Chk2, become activated and phosphory-
late p53 and/or MDM2, reducing the binding of MDM2 and
p53 (2, 40) and the inhibition of p53 nuclear export (49).
Overexpression of various oncogenes, including ras (31), myc
(52), E2F1 (1), and E1A (4), activates the transcription of the
ARF tumor suppressor, which in turn binds to MDM2 (33, 42,
50), consequently activating p53 by blocking p53 and MDM2
nuclear export and p53 cytoplasmic degradation (43, 48). On-
cogenic mutations targeting the components of either the
DNA damage-kinase-MDM2-p53 or the oncogenic insult-
ARF-MDM2-p53 pathway occur at high frequency in a wide
range of human tumors, demonstrating the critical function of
these two pathways in preventing tumor development in hu-
mans. In addition to ARF and DNA damage-activated kinases,
several additional cellular factors, such as Rb tumor suppres-
sor (12, 46), MDMX (14), and p300 histone acetyltransferase
(8, 9), have been reported to affect the function of p53 through
directly interacting with and regulating the activity of MDM2.
More recently, it was shown that mitogen-induced Akt physi-
cally associates with and phosphorylates MDM2, leading to an
enhanced activity of MDM2 and increased p53 degradation (7,
24, 27, 51). These findings support the notion that MDM2
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functions as the primary regulator of p53 and as an integrator
for the convergence of different stresses. To further explore the
potential of MDM2 in connecting cellular stress to p53, we
have undertaken a search for cellular factors that bind to and
regulate the function of MDM2.
MATERIALS AND METHODS
Plasmids, cell culture, and actinomycin D treatment. Mutant HDM2 and L11
constructs were generated by PCR-mediated site-directed mutagenesis and con-
firmed by direct DNA sequencing. U2OS, Saos-2, SJSA, and WI38 cells were
obtained from the American Type Culture Collection, and p53-MDM2 double-
deficient mouse embryonic fibroblasts were kindly provided by Steve Jones of the
University of Massachusetts (16). All cells were grown in cultures in a 37°C
incubator with 5% CO2 in Dulbecco modified Eagle medium supplemented with
10% fetal bovine serum. Procedures and conditions for cell transfections, im-
munoprecipitation (IP), and immunoblotting were as previously described (50).
For actinomycin D experiments, cells were treated with 5 nM actinomycin D for
the indicated time and analyzed for cell cycle progression by flow cytometry or
protein distribution by immunofluorescence microscopy.
In vitro transcription and translation and binding assays. Coupled in vitro
transcription and translation reactions were performed using a TNT kit (Pro-
mega) and following the manufacturer’s instructions. For in vitro binding assays,
translated proteins were mixed together and further incubated at 30°C for 30 min
in the same reticulocyte lysate. At the end of the incubation, 200 l of NP-40 lysis
buffer was added to each binding reaction followed by IP with appropriate
antibodies.
Antibodies. Affinity-purified rabbit polyclonal antibody to human MDM2 (N-
20; Santa Cruz), goat polyclonal antibody to human p53 (FL393; Santa Cruz),
mouse monoclonal antibodies to p53 (clone PAb421; Oncogene Science, Union-
dale, N.Y.), human MDM2 (clone SMP14; NeoMarkers), tubulin (clone DM1A
 DM1B; NeoMarkers), and actin (Sigma) were purchased commercially. Af-
finity-purified rabbit polyclonal antibody to mouse ARF was raised using a
synthetic peptide derived from the C terminus of the mouse ARF protein as an
immunogen. Rabbit polyclonal anti-human L11 antibody was produced using a
synthetic peptide, CIGAKHRISKEEAMRWFQQK, corresponding to amino
acid residues 149 to 168 of human L11.
Protein microsequencing. Ten 100-mm-diameter dishes of logarithmically
growing U2OS cells were transfected with pCMV-HDM2, and cell lysates were
pooled and immunoprecipitated with protein A beads covalently coated with
anti-HDM2 antibody (total, 1 mg). After extensive washing, the anti-HDM2
precipitates were resolved by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE). The gel was silver stained, and the resultant banding
patterns were compared with that observed by autoradiography of 35S IPs to
identify specific proteins. Proteins of interest were excised and subjected to in-gel
protease digestion (lysylendopeptidase; 50 ng/ml). Digested peptide fragments
were extracted by acetonitrile and separated by reverse-phase high-pressure
liquid chromatography (HPLC) on a Hewlett Packard 1100 HPLC system using
a C18 column (Vydac) (1 by 250 mm). Amino acid sequences of individual
peptides collected from HPLC were determined on an automated ABI micro-
sequencer.
Luciferase assays. At 24 h posttransfection, cells were washed in phosphate-
buffered saline and harvested by scraping into 250 l of 1 reporter lysis buffer
(Promega). The cells were lysed for 10 min at 4°C with rotation and clarified by
centrifugation for 5 min at 4°C in a microcentrifuge at maximum speed. A total
of 10 l of the clarified cell lysate was assayed for luciferase activity as described
previously (20). For -galactosidase assays, 75 l of the clarified lysate was
incubated at 37°C with 500 l of Z buffer (21 mM Na2HPO4, 40 mM NaH2PO4,
10 mM KCl, 1 mM MgSO4, 40 mM -mercaptoethanol, pH 7.0) containing
chlorophenolred--D-galactopyranoside (CPRG; Boehringer Mannheim, India-
napolis, Ind.) at a final concentration of 0.1 mg/ml. The reaction was stopped by
adding Na2CO3 to a final concentration of 260 mM, and the optical density at 595
nm was determined on a luminometer (Lumat LB 9501). The luciferase activity
for each sample was normalized to -galactosidase activity to control for trans-
fection efficiency. The normalized luciferase activity of the pGL2-Basic plasmid
was set to 1.
Cell transfection and FACS analysis. Cell transfections were carried out using
Lipofectamine reagent (Invitrogen) according to the manufacturer’s instructions
as described in detail previously (50). All cells were harvested at 24 h posttrans-
fection and analyzed for cell cycle distribution. For fluorescence-activated cell
sorter (FACS) analysis, cells were cotransfected with the indicated plasmid,
harvested by trypsinization, fixed in 70% ethanol, and stained with propidium
iodide (50 mg/ml) containing 50 mg of RNase A/ml. Flow cytometry analysis was
conducted using a Becton-Dickinson FACScan. Green fluorescent protein
(GFP) was used as a marker for the analysis of transfected cells. DNA content
data from at least 10,000 GFP-positive cells are presented in the DNA histo-
grams.
RESULTS
Identification of L11-HDM2 association. To identify novel
HDM2 interacting, and potentially regulatory, molecules, pro-
tein complex formation of HDM2 immunocomplexes was de-
termined by coupled metabolic labeling and IP (35S-IP). Anal-
ysis of HDM2 complexes revealed three cellular proteins with
apparent molecular masses of 35, 32, and 20 kDa that notice-
ably associated with HDM2 (Fig. 1A). Coexpression of both
p53 and ARF did not cause any detectable change of HDM2
association with p35, p32, or p20, suggesting that these proteins
do not interact with HDM2 in a competitive manner. To
determine the identities of p35, p32, and p20, we purified
the proteins in an HDM2 immunocomplex and subjected
them to protein microsequencing. Two peptide sequences,
VLEQLTGQTPVFSK and YDGIILPGK, matching perfectly
with human ribosomal protein L11 (residues 39 to 52 and
residues 170 to 178; Fig. 1B), were obtained for p20. Two
peptide sequences, GAVDGGLSIPHSTK and RFPGYD-
SESK, matching perfectly with human ribosomal protein L5
(residues 165 to 178 and residues 179 to 188; accession number
U14966), were obtained for p35. Human L11 and L5 proteins
contain 178 amino acid residues (20,190 Da) and 297 residues
(34,425 Da), respectively, corresponding to the sizes of p20 and
p35 detected in the HDM2 immunocomplex. Microsequencing
of p32 was not successful. Whether it corresponds to a distinct
polypeptide or an alternative translation initiation product of
L5 (37) remains to be determined. L5-MDM2 association was
previously reported (23), and our finding confirms this binding.
L11-HDM2 and L5-HDM2 associations do not require
RNA. Since L11 and L5 are ribosomal proteins that bind to
RNA and 5S and 5.8S RNAs have been reported to associate
with HDM2 as well as with the HDM2-p53 complex (23), we
determined whether an RNA component is required for the
interactions between L11 and L5 with HDM2. Treatment of
the cell lysate with RNaseA (10 g/ml) had no detectable effect
on L11-HDM2 and L5-HDM2 associations (Fig. 2A), indicat-
ing that RNA, although able to associate HDM2, is not re-
quired for HDM2 interaction with either ribosomal protein.
In vivo association of L11 with HDM2. An in vivo associa-
tion between L5 and HDM2 was previously demonstrated (23).
A rabbit polyclonal antibody specific to L11 was raised and
used to examine the in vivo binding of L11 and HDM2. L11
protein was readily detected in HDM2 immunocomplexes pre-
cipitated by three different HDM2 antibodies from human
SJSA osteosarcoma cells which have HDM2 amplification but
not in Saos-2 osteosarcoma cells which do not express detect-
able levels of HDM2 due to p53 deficiency (Fig. 2B). From
these results, we conclude that L11 readily associates with
HDM2 in vivo.
L11 binds to the central domain of HDM2. A series of
HDM2 deletion mutants was generated to map the L5 and L11
binding domains. Deletion of the N-terminal 216 (HDM2216-491)
and C-terminal 117 (HDM21-374) residues had no obvious effects
on HDM2-L5/L11 association (data not shown), suggesting that a
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sequence between HDM2 residues 216 and 374 is sufficient for
binding L5 and L11. To test this, we generated two smaller
HDM2 deletion mutants, HDM2216-374 and HDM2284-374, and
assessed their ability to bind with endogenous L5 and L11.
HDM2216-374 retained L5 and L11 binding activity (Fig. 3A). A
smaller HDM2 fragment, HDM2284-374, lost its ability to bind
with L5 but still retained full binding activity with L11. We there-
fore conclude that L11 can bind with HDM2 independently of L5
and possibly facilitates L5-HDM2 binding.
We also generated several L11 deletion mutants to map the
HDM2 binding domain in L11 (Fig. 3B). Deletion of either the
C-terminal 53 residues (L111-125) or N-terminal 62 residues
(L1163-178) reduced, but did not completely disrupt, HDM2
binding, whereas deletion of a central sequence containing
residues 63 to 125 completely abolished HDM2 binding. These
results indicate that the central region of L11 is required for
binding with HDM2.
L11 can form a quaternary complex with HDM2, p53 and
ARF. A series of reciprocal IP-Western blotting assays were
carried out to determine the interactions between L11, HDM2,
p53, and ARF (Fig. 4). U2OS cells were transiently transfected
with various combinations of plasmids expressing these pro-
teins. L11/HDM2 complexes were detected reciprocally in cells
expressing both proteins (lanes 3 to 6 and 9 to 12). Coexpres-
sion of L11 and HDM2 with ARF, p53, or both did not no-
ticeably affect L11-HDM2 binding (lanes 4 to 6 and 10 to 12)
and, importantly, L11 was detected in ARF and p53 immuno-
complexes when HDM2 was coexpressed (lanes 13 to 24).
Hence, L11, ARF, and p53 do not compete for binding with
HDM2 and can simultaneously bind HDM2 to form a multi-
protein complex. This conclusion is supported by the deletion
analysis results showing that ARF and L11 bind to two sepa-
rate sequences in HDM2, with amino acids 284 to 374 retain-
ing full binding activity with L11 (Fig. 3A) and ARF binding to
the region containing amino acids 210 to 244 of HDM2 (25).
L11 reduces HDM2-mediated p53 ubiquitination and stabi-
lizes p53. HDM2 functions as an E3 ligase to ubiquitinate p53
and promotes p53 degradation (11). To examine whether L11
interferes with HDM2-mediated p53 ubiquitination in vivo,
U2OS cells were cotransfected with plasmids expressing hem-
agglutinin (HA)-epitope-tagged ubiquitin, p53, and HDM2. At
36 h after transfection, proteasome inhibitor MG132 was
added to inhibit the degradation of polyubiquitinated proteins.
The expression of various proteins was confirmed by direct
FIG. 1. Analysis of HDM2 immunocomplex and identification of HDM2-L11 association. (A) HeLa cells were transiently transfected with
plasmid DNA expressing HDM2. At 24 h after transfection, cells were metabolically labeled with [35S]methionine and the lysates were immuno-
precipitated with antibody to HDM2. Immunoprecipitated proteins were separated by SDS-PAGE and visualized by autoradiography. The
molecular identities of L5 and L11 were determined by protein microsequencing following a preparative anti-HDM2 IP. The identity of the 32-kDa
protein (p32) has not yet been established. (B) HDM2-associated p20 corresponds to human ribosomal protein L11. L11 protein contains a
putative nuclear export signal (NES) and a nuclear and nucleolar localization signal (NLS/NoLS). Two peptide sequences were obtained from
protein microsequencing; both matched perfectly with human L11.
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immunoblotting, and accumulation of ubiquitinated p53 was
examined by blotting anti-p53 immunoprecipitates with an-
ti-HA antibody (Fig. 5A). Coexpression of HDM2 with p53
resulted in an accumulation of a high-molecular-weight p53
smear characteristic of polyubiquitinated p53. Ubiquitinated
p53 was not detected when either HDM2 or p53 was omitted
or when a catalytically inactive RING finger mutant of HDM2
(C464A) was used (data not shown). Coexpression of L11 with
HDM2 and p53 (lane 8), like that of ARF (lane 7), almost
completely blocked the accumulation of polyubiquitinated p53.
Consistent with the decrease of p53 ubiquitination, L11, like
ARF, prevented HDM2-mediated p53 degradation, resulting
in an increase in the steady-state level of p53 protein in the
presence of HDM2 (Fig. 5B). These results demonstrate that
L11 protein interferes with HDM2-mediated p53 ubiquitina-
tion and subsequent degradation to stabilize p53 protein levels.
The steady-state level of HDM2 itself was also increased by the
coexpression of either ARF or L11; this is consistent with the
idea that L11, like ARF, inhibits both the ubiquitin ligase
activity of HDM2 toward its substrate, p53, and HDM2’s
autoubiquitin ligase activity.
L11 abolishes the inhibition of p53 transactivation by
HDM2. We then determined the effect of the presence of L11
on the HDM2-mediated repression of p53 transactivation ac-
tivity. Under the conditions in which HDM2 almost completely
repressed p53-dependent transactivation from the pGL13-Luc
reporter, cotransfection with an L11 expression plasmid re-
stored up to 70% of p53 transactivation activity (Fig. 6A and
B).
Cotransfection of a plasmid expressing L5 had a negligible
effect on the HDM2-mediated repression of p53 transactiva-
tion (Fig. 6B), indicating that even when overexpressed, L5
alone does not significantly affect the ability of HDM2 to
repress p53. This result is consistent with our observations that
L11 can bind with HDM2 independently of L5, supporting the
notion that L5 is not required for the function of L11 in HDM2
regulation. Deletion of either N-terminal (L1163-178 and
L11126-178) or C-terminal (L111-63 and L111-125) sequences
eliminated the ability of L11 to repress HDM2 inhibition of
p53 (Fig. 6B). Both L111-125 and L1163-178 mutants retained a
partial HDM2 binding activity (Fig. 3B). These results suggest
that additional sequences in L11 other than those simply re-
quired for HDM2 binding are necessary to block HDM2 func-
tion.
Ectopic expression of L11 resulted in a dose-dependent in-
crease in the steady-state level of endogenous p53 protein in
U2OS cells, as previously observed, while overexpression of
p53 did not appear to significantly affect L11 protein level (Fig.
6C). Notably, this was coupled with a parallel increase in p21
FIG. 2. HDM2 interacts with ribosomal protein L11. (A) U2OS cells were transiently transfected with plasmid expressing HDM2. Transfected
cells were lysed in the presence () or absence () of RNaseA (10 g/ml). HDM2-L11/L5 complexes were examined by IP with an -HDM2
antibody. No obvious effect was observed on L11-Hdm2 association after the RNaseA treatment. (B) L11 associates with HDM2 in vivo.
Asynchronously growing human SJSA cells or HDM2-negative Saos-2 cells were lysed and immunoprecipitated with antibodies recognizing L11
and HDM2.
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levels, suggesting that expression of L11 can stabilize endoge-
nous p53 to activate p21.
Ectopic expression of L11 blocks S-phase entry dependent
on p53. To determine whether overexpression of L11 is able to
induce a p53-dependent cell cycle arrest, L11 was transiently
transfected into U2OS (which contains functional p53) and
Saos-2 (p53-defective) cells and the cell cycle distribution was
determined by flow cytometry analysis (FACS). Cells were
simultaneously transfected with a plasmid expressing GFP for
gating the positively transfected cells. As shown in Fig. 7A,
overexpression of L11 blocked S-phase entry in U2OS but not
in Saos-2 cells, indicating that L11 induces a cell cycle arrest
dependent on the presence of p53. Previous studies have
shown that ARF can reverse the MDM2-inhibited p53 func-
tion to induce cell cycle arrest. To address whether L11 has a
similar function, we carried out FACS analysis with U2OS cells
transiently transfected with L11, HDM2, and p53 (Fig. 7B). As
shown previously, expression of p53 blocked cell cycle progres-
sion into the S phase and this was abolished by coexpression of
HDM2. In cells transfected with p53 and MDM2, cotransfec-
tion with L11, but not with another HDM2-binding ribosomal
protein, L5 (23), restored S-phase entry to a level comparable
to that seen in cells cotransfected with ARF, indicating a spe-
cific function of L11 in reversing HDM2 inhibition of p53
activity.
Ribosomal stress induced by a low concentration of actino-
mycin D increases L11-MDM2 interaction and stabilizes p53.
In search of biological functions of the L11-HDM2-p53 path-
way, we hypothesized that since it is a ribosomal protein, L11
functions in monitoring ribosomal biogenesis and cell growth.
To test this idea, we first determined the nature of HDM2-L11
interactions in mediating ribosomal biogenesis by treating cells
with low concentrations of actinomycin D. At high concentra-
tions (e.g., 30 nM) actinomycin D causes DNA damage and
inhibits transcription from all three classes of RNA polymerase
promoters, whereas at low concentrations (e.g., 10 nM) ac-
FIG. 3. L11 binds to a central domain in HDM2. (A) Mapping of L11 binding domain in HDM2. Wild-type HDM2-expressing plasmids were
transiently transfected into U2OS cells. At 24 h after transfection, cells were metabolically labeled with [35S]methionine and the lysates were
immunoprecipitated with antibody to HDM2. (B) Mapping of HDM2 binding domain in L11. WT, wild type.
8906 ZHANG ET AL. MOL. CELL. BIOL.
tinomycin D selectively inhibits RNA pol I-dependent tran-
scription and thus ribosomal biogenesis (13, 32). The binding
of L11 with HDM2 was barely detectable under normal con-
ditions, presumably because the majority of L11 was bound to
60S ribosomal subunits either in the nucleolus or in the cyto-
plasm (Fig. 8A). Treating WI38 cells with 5 nM of actinomycin
D apparently did not affect the level of endogenous L11 but
clearly increased the levels of endogenous HDM2 and the
L11-HDM2 complex (Fig. 8A). Consequently, upon actinomy-
cin D treatment the levels of p53 and the HDM2-bound p53
were also increased (Fig. 8B). To rule out the possibility that
the increase in the HDM2-L11 interaction was solely due to an
FIG. 4. L11 can form quaternary complexes with HDM2, p53, and ARF. U2OS cells were transiently transfected with () or without ()
plasmid DNA expressing HDM2, p53, and HA-ARF as indicated. At 24 h after transfection, cells were lysed and immunoprecipitated with the
indicated antibodies followed by immunoblotting.
FIG. 5. L11 inhibits HDM2-mediated p53 ubiquitination and degradation. (A) U2OS cells were transfected with () or without () the
indicated plasmids. At 36 h after transfection, cells were treated with proteasome inhibitor MG132 (50 M) for 4 h prior to cell lysis. Clarified cell
lysate was immunoprecipitated (IP) with anti-p53 antibody, and washed immunoprecipitates were resolved by SDS-PAGE followed by immuno-
blotting with anti-HA antibody. Expression of individual transfected proteins was determined by direct immunoblotting (bottom panels). WB,
Western blotting. (B) Total lysates prepared from cells transfected with () or without () the indicated plasmids were electrophoretically
separated before immunoblotting with the indicated antibodies was performed.
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increase of HDM2, cells were treated with the proteasome
inhibitor MG132, alone or in combination with actinomycin D
treatment, to stabilize and accumulate HDM2 protein before
lysis. Although both cell populations accumulated HDM2 pro-
tein to similar levels, L11-HDM2 complex was readily detected
in the cells treated with combination of MG132 and actinomy-
cin D but was almost undetectable in cells treated with MG132
alone (Fig. 8C). Hence, perturbation of ribosomal assembly by
actinomycin D enhances L11-HDM2 association.
To further substantiate the notion that actinomycin D-
induced ribosomal stress, but not other types of stress, spe-
cifically increased L11-HDM2 binding, we have examined
L11-HDM2 interaction in cells that sustained several addi-
tional stresses. Exposure of WI38 cells to UV irradiation
accumulated HDM2 but did not increase L11-HDM2 asso-
ciation (Fig. 8D). Likewise, we found that overexpression of
E2F1, which, like overexpression of several other growth-
promoting oncogenes, stimulated the transcription of ARF
and accumulated HDM2 and p53, did not appreciably affect
the level of either L11 protein or L11-HDM2 association
(data not shown). These results suggest that L11 does not
play a major role in cellular response to either DNA damage
or hyperproliferation induced by oncogene overexpression
and instead specifically regulates a HDM2-p53 response to
ribosomal perturbation.
DISCUSSION
In this study, we provide evidence for a physical interaction
and functional regulation between ribosomal protein L11, a
component of cell growth machinery, and HDM2, a key regu-
lator of p53-mediated checkpoint pathways. First, L11 directly
binds with HDM2 via its central domain and can form a ter-
nary complex with p53. Second, L11 inhibits HDM2-promoted
p53 ubiquitination to subsequently stabilize p53 protein levels.
Third, L11 expression relieves HDM2-mediated repression of
p53 transactivation and can activate endogenous p53.
The 491 residues of HDM2 can be divided into three func-
tional domains: an N-terminal region which binds p53, a C-
terminal RING finger domain that promotes p53 ubiquitina-
tion, and a central region of approximately 300 residues that
contains multiple sites for binding and regulation by different
proteins, including RB (12, 46), ARF (33, 42, 50), p300 histone
acetyltransferase (9) Akt (in phosphorylation) (7, 24, 27, 51),
and now L11 (see Fig. 3A for a schematic summary). These
findings attest to the notion that the central 300-amino-acid
domain of MDM2/HDM2 contains multiple sites for the bind-
ing of various cellular factors to channel multiple stress path-
ways into p53 control.
The activity residing in this region has long been elusive. We
have found that L11 ribosomal protein binds HDM2 via this
central domain (Fig. 3), providing the first functional assign-
FIG. 6. L11 relieves HDM2-mediated repression of p53 transactivation. (A and B) U2OS cells were cotransfected with () or without ()
pGL13-Luc reporter plasmids and plasmids expressing indicated proteins. At 24 h after transfection, clarified cell lysates prepared from each
transfected cell population were incubated with a luciferase assay buffer and the optical density at 595 nm was determined on a luminometer. The
luciferase activity for each sample was normalized to -galactosidase activity to control for transfection efficiency. The normalized luciferase activity
of the pGL2-Basic plasmid was set to 1. (C) Total lysates prepared from cells transfected with the indicated plasmids were electrophoretically
separated before immunoblotting with () or without () the indicated antibodies was performed. CMV, cytomegalovirus.
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ment to this region. It is intriguing that L11 regulates HDM2
and p53 in a manner similar to the regulation of HDM2 and
p53 by ARF. Both L11 and ARF normally localize to the
nucleolus and relocalize to interact with HDM2 in the nucle-
oplasm (21, 48), both can bind directly with HDM2 and form
ternary complexes with p53 and HDM2, and both inhibit
HDM2-promoted p53 ubiquitination and restore p53’s trans-
activating activity in the presence of HDM2. There is, however,
one notable distinction between L11- and ARF-mediated
HDM2 regulation mechanisms. ARF inhibits HDM2’s nuclear
export, whereas L11 does not (reference 48 and our unpub-
lished results). We suspect that binding of ARF and L11 to two
different, nonoverlapping sequences in HDM2 can contribute
to this mechanistic difference. ARF has been suggested to link
FIG. 7. L11 induces a p53-dependent cell cycle arrest. (A) U2OS or Saos-2 cells were transfected with or without (Vector) a plasmid expressing
a GFP marker and the indicated proteins. (B) U2OS cells were cotransfected with or without (Vector) a plasmid expressing a GFP marker and
the indicated proteins. Transfected cells were sorted, and their cell cycle distribution characteristics were determined by flow cytometry at 24 h after
transfection. The proportions of cells in S phase in each transfected cell population were compared using bar graphs. A minimum of 10,000
GFP-positive cells were analyzed for each transfection.
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oncogene-induced hyperproliferative signals to p53-dependent
cell cycle arrest (39). By transfection and co-IP assays, we
observed the formation of a p53-HDM2-ARF-L11 quaternary
complex (Fig. 4). Assembly of such a quaternary complex
raises the intriguing possibility that in cells experiencing two
insults at the same time, one causing a ribosomal perturbation
or growth inhibition and one stimulating cells to hyperprolif-
erate, L11 and ARF can in theory simultaneously bind to
HDM2 to additively inhibit HDM2 and induce a more rapid
and effective cell cycle arrest.
How L11 inhibits HDM2 ubiquitin ligase activity, as in the
case of ARF-mediated inhibition of MDM2 ubiquitin ligase
activity, is not clear. In vitro, the RING finger domain of
HDM2 alone is sufficient to catalyze the synthesis of polyubiq-
uitin chain (autoubiquitination) and association of L11 with
HDM2 does not inhibit HDM2-mediated p53 ubiquitination
(M. Furukawa, J. McCarville, and Y. Xiong, unpublished
data); this suggests that an additional factor(s) is involved in
L11 inhibition of HDM2-mediated p53 ubiquitination in vivo.
Further investigation of the mechanism of L11 inhibition will
provide insights into inhibition of HDM2 activity and ubiquitin
ligase activity in general.
In yeast species such as Saccharomyces cerevisiae, cell cycle
arrest results in response to increased cellular size while nu-
trient deprivation coordinately blocks both cell growth and cell
cycle, indicating that sufficient cell growth is required for and
must regulate the progression of the cell cycle (15). Similar
observations have also recently been reported regarding mam-
malian cells (6). Ribosomal biogenesis includes the expression
of approximately 150 rRNA genes and the synthesis of nearly
80 ribosomal proteins and a large number of assembly factors
and consumes up to 80% of the energy of a proliferating cell
(reviewed in references 18 and 44). Ribosomal assembly must
therefore be tightly regulated for the economy of the cell and
rapidly responsive to various environmental and intracellular
growth conditions or insults. As the major component of cell
growth, ribosome biogenesis could conceivably be the target of
a checkpoint pathway for monitoring cell growth and coupling
a growth condition change or insult to the cell cycle. A mam-
malian ribosome contains 77 ribosomal proteins, and the func-
tion of most ribosomal protein subunits has not been investi-
gated individually. We suggest that the L11-HDM2-p53
pathway functions in monitoring ribosome biogenesis and cou-
ples cell growth to the cell cycle (Fig. 9). We postulate that L11
is constantly swinging between binding with HDM2 in the
nucleoplasm and being assembled into ribosomes, with the
latter activity exhibiting higher affinity and being more preva-
lent than L11’s association with HDM2. A signal stimulating
cell growth would promote L11 assembly into functional ribo-
somes, allowing HDM2 to repress p53 and thereby linking
increased cell growth (protein synthesis) with a reduced
threshold (e.g., p21 level) for entering the S phase. An inhibi-
tion of cell growth that decreases ribosome biogenesis or a
direct perturbation of ribosomal biogenesis would release L11
FIG. 8. Perturbation of ribosomal biogenesis by actinomycin D (ActD) increases L11-HDM2-p53 complex levels. (A and B) WI38 cells were
treated with 5 nM actinomycin D for 24 h () or left untreated () before being lysed for analysis for the expression of various proteins and protein
complex formation. Approximately 500 ug of total protein was utilized for each IP. (C) WI38 cells were treated with the proteasome inhibitor
MG132 for 6 h before lysis to stabilize HDM2 in the presence () or absence () of 5 nM actinomycin D. A total of 200 ug of protein was used
in each IP. (D) WI38 cells were treated with UV (50 J/m2) () at 24 h before harvesting or left untreated (), and IP was performed as described
above.
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to bind with HDM2, leading to increased p53 activity and
lowering the threshold of entry into a proliferative cycle.
The findings reported here raise a number of other ques-
tions. Given that L11 is highly conserved during evolution, the
p53 gene is conserved in Drosophila, and Mdm2 is present in all
known vertebrates (e.g., frogs, zebra fish, and mammals), could
L11’s regulatory effect toward p53 (and thus, coupling of cel-
lular growth to the cell cycle) have evolved as early as or prior
to the divergence of vertebrates? In mammals, MDM2 has a
closely related homologue, MDMX, that also binds to and
negatively regulates p53 (41). MDMX shares with MDM2 sim-
ilar overall structural organizations including the conserved
central zinc finger domain. Does L11 similarly regulate
MDMX? MDMX functions in part by interacting with MDM2
(38). Could L11 influence the MDM2-MDMX interaction or
MDMX affect L11-mediated regulation on MDM2? Lastly,
both Rb family proteins and p53 have been reported to nega-
tively regulate Pol I-dependent rRNA transcription (recently
reviewed by Ruggero and Pandolfi) (36). Could the L11-
Mdm2-p53 pathway and the Rb/p53-Pol I pathway be inter-
twined on a feedback loop to positively regulate each other?
Studies of these questions could help lead us to a better un-
derstanding of how cell growth control is coordinated with cell
cycle regulation and are experimentally possible.
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